<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2919">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535674</url>
  </required_header>
  <id_info>
    <org_study_id>APG101_CD_017</org_study_id>
    <secondary_id>2020-001887-27</secondary_id>
    <nct_id>NCT04535674</nct_id>
  </id_info>
  <brief_title>Asunercept in Patients With Severe COVID-19</brief_title>
  <acronym>ASUNCTIS</acronym>
  <official_title>A Multicenter, Randomised, Controlled, Open Label Trial on the Efficacy and Safety of Asunercept for Patients With Severe COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apogenix AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apogenix AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, phase II study with the main objective to investigate the&#xD;
      effectiveness and safety of an investigational drug (APG101; International Nonproprietary&#xD;
      Name: asunercept) in patients with severe COVID-19 disease. The study aims to decrease&#xD;
      overall and SARS-CoV-2 associated pneumonia mortality in patients with COVID-19 as well as to&#xD;
      decrease the percentage of patients admitted to Intensive Care Unit (ICU), decrease the need&#xD;
      to supply oxygen to patients, reduce the number of days patients are hospitalized in ICU&#xD;
      and/or on the ward, decrease the number of days required to obtain a negative result in the&#xD;
      PCR (Polymerase Chain Reaction, a laboratory technique that allows the amplification of small&#xD;
      fragments of DNA to detect the presence of the virus) test for COVID-19 and decrease the&#xD;
      levels of markers that indicate pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Asunercept/APG101 will be tested in three parallel intervention arms and compared with Standard of Care (SoC). The study will compare treatment efficacy of SoC to that of weekly intravenous infusions of Asunercept at three different doses. Patients will be randomised into four groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to sustained improvement of one category (i.e. two consecutive days) from randomisation</measure>
    <time_frame>Day 1-29</time_frame>
    <description>The primary endpoint is time to clinical improvement which is defined as time from randomisation to an (sustained) improvement of at least one category on two consecutive days compared to the status at randomisation measured on a nine-category ordinal scale (proposed by WHO).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy according to the National Early Warning Score (NEWS)</measure>
    <time_frame>Day 1-29</time_frame>
    <description>Time to discharge or to a NEWS of ≤2 and maintained for 24 hours, whichever occurs first Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation</measure>
    <time_frame>Day 1-29</time_frame>
    <description>Oxygenation free days until day 29 Incidence and duration of new oxygen use during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilation</measure>
    <time_frame>Day 1-29</time_frame>
    <description>Ventilator free days until day 29 Incidence and duration fo new mechanical ventilation use during the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation - Length</measure>
    <time_frame>Day 1-29</time_frame>
    <description>Duration of hospitalisation Length of ICU stay (in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation - Proportion on ICU</measure>
    <time_frame>Day 1-29</time_frame>
    <description>Proportion of patients admitted to ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>15-day, 29-day, 60-day and 90-day all-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19 Induced Pneumonia</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care + Asunercept 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care + Asunercept 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care + Asunercept 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Asunercept</intervention_name>
    <description>Asunercept (APG101) will be administered once per week as an i.v. infusion</description>
    <arm_group_label>Standard of Care + Asunercept 100 mg</arm_group_label>
    <arm_group_label>Standard of Care + Asunercept 25 mg</arm_group_label>
    <arm_group_label>Standard of Care + Asunercept 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Laboratory confirmed infection with SARS-CoV-2 OR typical radiological signs of&#xD;
             SARS-CoV-2 infection&#xD;
&#xD;
          -  Hospitalisation due to COVID-19&#xD;
&#xD;
          -  Informed Consent obtained, the patient understands and agrees to comply with the&#xD;
             planned study procedures. If a potential patient is unconscious, the Patient&#xD;
             Information Sheet with the Informed Consent Form can be signed by the legal&#xD;
             representative, if he/she accompanies the patient. It can be signed by a Concilium&#xD;
             consisting of doctors (2), investigator and an independent witness in case the legal&#xD;
             representative is not available.&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  Willingness to perform effective measures of contraception during the study.&#xD;
&#xD;
          -  Signs of respiratory deterioration such as oxygen saturation ≤94% when breathing&#xD;
             ambient air or &gt;3% drop in oxygen saturation in case of chronic obstructive lung&#xD;
             disease OR need for oxygen supplementation to achieve satisfactory blood oxygen&#xD;
             saturation (sPO2&gt;90% at room air) as well as the need for non-invasive ventilation,&#xD;
             high-flow oxygen devices or mechanical ventilation or radiological or clinical signs&#xD;
             of pneumonia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Moribund, or estimated life expectancy &lt;1 month (e.g., terminal cancer, etc.)&#xD;
&#xD;
          -  Patient does not qualify for intensive care, based on local triage criteria&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Severe liver dysfunction (e.g. ALT/AST &gt; 5 times upper limit of normal)&#xD;
&#xD;
          -  Anticipated discharge from hospital within 48 hours&#xD;
&#xD;
          -  Other potent anti-inflammatory treatment, e.g. TNF- blocking therapies&#xD;
&#xD;
          -  Mechanical ventilation for &gt;48 hours&#xD;
&#xD;
          -  Known active HIV or viral hepatitis infection&#xD;
&#xD;
          -  Known active tuberculosis&#xD;
&#xD;
          -  Known hereditary fructose intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pilar Ruiz-Seco, PhD-MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Infanta Sofía, Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carola Straub</last_name>
    <phone>+49 6221 58608</phone>
    <phone_ext>72</phone_ext>
    <email>carola.straub@apogenix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Kuban State Medical University&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Igor Zabolotskikh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution &quot;Scientific Research Institute - Regional clinical hospital No. 1 n.a. professor S.V. Ochapovsky&quot; of the Ministry of Healthcare of Krasnodar Krai</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zoya Tatarintseva</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Health of the Nizhny Novgorod Region &quot;Infectious Clinical Hospital No. 2 of Nizhny Novgorod&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Tikhomolova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg state budgetary healthcare institution &quot;Botkin clinical infectious diseases hospital&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis Gusev</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg state budgetary healthcare institution &quot;City hospital of Saint George the great Martyr&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Ivanov</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Budgetary Healthcare Institution &quot;Mariinskaya City hospital&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalya Gonchar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Bashkir State Medical University&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bulat Bakirov</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Bashkir State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Damir Valishin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Ramos-Bárbon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Duffort Falcó</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergio Diz Farina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Callejas Díaz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofia</name>
      <address>
        <city>San Sebastián De Los Reyes</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Suarez Garcia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Ramon Pano Pardo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

